A gut-lung connection influences susceptibility to infection by Acinetobacter baumannii, a leading cause of hospital-acquired ...

A new study from Vanderbilt Health and the University of Chicago finds that antibiotics can disrupt gut microbiota, weakening lung immune defenses and worsening hospital-acquired pneumonia caused by ...

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...

A gut-lung connection influences susceptibility to infection by Acinetobacter baumannii, a leading cause of hospital-acquired ...

Antimicrobial resistance to common bacteria is rising worldwide, eroding the effectiveness of last-line antibiotics against ...

BioVersys has begun patient dosing in its global pivotal Phase 3 RIV-TARGET trial of BV100, an intravenous rifabutin formulation for hospital-acquired and ventilator-associated bacterial pneumonia ...

Acinetobacter baumannii represents a formidable nosocomial pathogen, largely due to its rapid acquisition of multidrug resistance and its capacity to cause severe infections. This Gram‐negative ...

November 4, 2009 (Philadelphia, Pennsylvania) — Multidrug-resistant (MDR) Acinetobacter baumannii (ACBA) is a persistent threat to hospitalized patients, whether the infection is acquired in the ...

Researchers have engineered a library of strains that can be used to develop new antibacterial compounds to help address antimicrobial resistance (AMR) in Acinetobacter baumannii bacteria. University ...

Dar es Salaam. A comprehensive new study has raised concern over a “critical and troubling” rise in antimicrobial resistance (AMR) across Tanzania, showing that many commonly used antibiotics are ...

The carbapenem antibiotics (imipenem, meropenem and doripenem) are considered the agents of choice for A. baumannii infections. The presence of resistance to these agents constrains therapeutic ...